A Trial In Diabetic Patients To Assess Effect Of CE-326,597 On Glucose Control And Body Weight
NCT00542009
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
Patients with type 2 diabetes, not on any or on oral (up to 2) anti-diabetic medications, otherwise medically stable.
Women of childbearing potential, people with unstable medical conditions, people with
gallstones
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Phoenix, Arizona
- Fresno, California
- National City, California
- San Diego, California
- Miami, Florida
- Ocala, Florida
- West Palm Beach, Florida
- Atlanta, Georgia
- Conyers, Georgia
- Honolulu, Hawaii
- Idaho Falls, Idaho
- Chicago, Illinois
- Chicago, Illinois
- Overland Park, Kansas
- Bethesda, Maryland
- Chaska, Minnesota
- Minneapolis, Minnesota
- Jackson, Mississippi
- Henderson, Nevada
- Las Vegas, Nevada
- Las Vegas, Nevada
- Fargo, North Dakota
- Cincinnati, Ohio
- Lansdale, Pennsylvania
- Rapid City, South Dakota
- Beaumont, Texas
- Beaumont, Texas
- Dallas, Texas
- Dallas, Texas
- Richmond, Virginia
- Pleven,
- Sofia,
- Sofia,
- Stara Zagora,
- Coquitlam, British Columbia
- Winnipeg, Manitoba
- Winnipeg, Manitoba
- London, Ontario
- Laval, Quebec
- Montreal, Quebec
- Bangalore, Karnataka
- Indore, Madhya Pradesh
- Nagpur, Maharashtra
- Nasik, Maharashtra
- Ladron de Guevara, Guadalajara, Jalisco
- Guadalajara, Jalisco
- Monterrey, Nuevo Leon
- Ponce,
- San Juan,
- Tao Baja,
- Santiago de Compostela, La Coruña
- Barcelona,
- Madrid,
- Sevilla,
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | A Trial In Diabetic Patients To Assess Effect Of CE-326,597 On Glucose Control And Body Weight | |||
Official Title ICMJE | A 12-Week, Phase 2A, Randomized, Subject And Investigator Blinded, Placebo-Controlled Trial To Evaluate The Safety, Tolerability And Efficacy Of CE-326,597 On Glucose Control And Body Weight In Overweight Adult Subjects With Type 2 Diabetes Mellitus | |||
Brief Summary | Study of whether the investigational drug CE-326,597 improves glucose control and results in body weight loss in patients with type 2 diabetes | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 2 | |||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double (Participant, Investigator) Primary Purpose: Treatment | |||
Condition ICMJE |
| |||
Intervention ICMJE |
| |||
Study Arms ICMJE |
| |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Actual Enrollment ICMJE | 252 | |||
Original Enrollment ICMJE | 200 | |||
Actual Study Completion Date ICMJE | November 2008 | |||
Actual Primary Completion Date | November 2008 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria ICMJE | Inclusion Criteria: Patients with type 2 diabetes, not on any or on oral (up to 2) anti-diabetic medications, otherwise medically stable. Exclusion Criteria: Women of childbearing potential, people with unstable medical conditions, people with gallstones | |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 18 Years to 65 Years (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | Bulgaria, Canada, India, Mexico, Puerto Rico, Spain, United States | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT00542009 | |||
Other Study ID Numbers ICMJE | A7211005 | |||
Has Data Monitoring Committee | No | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Pfizer | |||
Study Sponsor ICMJE | Pfizer | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
| |||
PRS Account | Pfizer | |||
Verification Date | November 2012 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |